Detection and Confirmation of *Mycoplasma pneumoniae* in Urogenital Specimens by PCR

S. SHARMA, R. BROUSSEAU, and S. KASATIA

Ottawa Public Health Laboratory and Department of Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, and Environmental Genetics Sector, Biotechnology Research Institute, National Research Council, Montreal, Canada

Received 18 April 1997/Returned for modification 5 August 1997/Accepted 20 October 1997

Following the isolation of *Mycoplasma pneumoniae* from urogenital specimens (M. Goulet, R. Dular, J. G. Tully, G. Billows, and S. Kasatiya, J. Clin. Microbiol. 33:2823–2825, 1995), a study was undertaken to confirm the observations by PCR. Specific primers directed to the P1 adhesin gene of *Mycoplasma pneumoniae* were used. A total of 300 genital specimens were tested for *M. pneumoniae* and *Mycoplasma genitalium* by culture and PCR. Of these, 15 were positive by culture and 17 were positive by PCR for *M. pneumoniae*. No *M. genitalium* was detected in any of the specimens by either method. The present study demonstrates that PCR is sensitive and rapid compared to cumbersome culture methods and can be used to detect *M. pneumoniae* in urogenital specimens in a routine diagnostic laboratory.

*Mycoplasma pneumoniae* is a pathogen primarily of the human respiratory tract. However, it has been found to be associated with a varied range of extrapulmonary complications, with mild to severe symptoms (9, 13). Isolation of *M. pneumoniae* from a tubo-ovarian abscess and from three cases of vaginal infections has been reported previously (19).

The detection of *M. pneumoniae* by culture methods requires 3 to 4 weeks (15). Routine serological methods for the detection of *M. pneumoniae* infections are limited by a significant degree of variability and nonspecificity (2). Although immunoglobulin M assays partially overcome these difficulties, they also have limitations (17). In addition, it has been shown that *M. pneumoniae* has some of the same protein and lipid antigenic determinants as *Mycoplasma genitalium* (12). Cross-reactive epitopes have been detected among several proteins, including the large (170 kDa) surface membrane protein P1 of *M. pneumoniae* and the 140-kDa protein of *M. genitalium*, which are believed to mediate mycoplasma adherence to host cells (14). Although these microorganisms appear to have similar morphologies, limited DNA homology (1.8 to 8% based on total genomic DNA-DNA hybridization tests) exists between *M. genitalium* and *M. pneumoniae* (6). These difficulties have led to the development of PCR methods for these fastidious microorganisms (18). Recently, PCR has been chosen to detect *M. genitalium* (7), *Ureaplasma urealyticum*, and *Mycoplasma hominis* (11). Deguchi et al. (7) suggested that PCR is much more sensitive than culture in detecting *M. genitalium*.

Initially, our interest in this area arose due to a coincidental isolation of *M. pneumoniae* from a cervical swab submitted to our laboratory by a gynecological clinic for routine isolation of genital mycoplasmas. This rare observation prompted an investigation to determine the presence of *M. pneumoniae* in urogenital specimens, leading to the isolation of 24 strains of *M. pneumoniae* (10). *M. genitalium* has been isolated from the respiratory as well as the genital area (1). Also, *M. pneumoniae* and *M. genitalium* were both isolated from synovial fluid (21), suggesting that these two organisms can occur together. These findings and our recent isolation of *M. pneumoniae* in urogenital specimens (10) led us to initiate a study to detect *M. pneumoniae* by PCR in urogenital specimens as well as to differentiate *M. pneumoniae* and *M. genitalium* directly in urogenital specimens.

*M. pneumoniae* (ATCC 15531) and *M. genitalium* (ATCC 33530) were purchased from the American Type Culture Collection (Rockville, Md.). The mycoplasma strains were cultured in SP-4 medium (22) containing 2,000 U of penicillin G ml⁻¹ and 2.5 μg of amphotericin B ml⁻¹. Thallium acetate was not added to the medium, since it can inhibit the growth of *M. genitalium* (20).

Urogenital specimens were obtained from 300 patients. Most samples were cervical swabs, but pelvic fluid and urine samples were also obtained. A few urethral swabs were obtained from male patients. The ages of the patients ranged from 17 to 51 years. The patients did not report a history of respiratory disease during the 6 months prior to specimen collection, and most patients belonged to a socioeconomic group that, on average, had a low risk of contracting sexually transmitted diseases.

Endocervical swabs were collected and inoculated into a transport medium (8) and then transferred to the laboratory within 24 h. Urethral swabs taken from male patients were also transferred to transport medium for cultivation attempts. The specimens were processed on arrival or after storage at –70°C. A portion of the specimen was processed for culture, while the remaining volume was prepared for PCR as described below.

An aliquot (0.2 ml) of the sample in transport medium was inoculated into each of the following media: U9 broth and modified (A7B) agar for *Ureaplasma urealyticum* isolation and identification (16), arginine broth (23), SP-4 broth (20), and mycoplasma broth and agar (8) for the isolation of mycoplasmas. All broth cultures were incubated at 37°C and were examined every 3rd day for turbidity and a pH change over an 8-week period. The broth cultures were subcultured onto agar plates at 5-, 10-, and 15-day intervals. Agar plates were incubated at 37°C in a 10% carbon dioxide environment and were examined weekly over an 8-week period for potential *M. pneumoniae* or *M. genitalium* colonies and tested for hemadsorption and hemolysis.

DNA from different mycoplasma strains and clinical samples...
was prepared for PCR as described by Cadieux et al. (3). Briefly, the sample (about 100 μl) was centrifuged at 14,000 rpm for 20 min, washed in phosphate-buffered saline (0.1 M NaCl, 2.5 mM KCl, 10 mM Na₂HPO₄, 1.5 mM KH₂PO₄ [pH 7.4]), and resuspended in 60 μl of distilled water. The sample was then boiled for 5 to 10 min and stored at 4°C.

The primers were synthesized on an Applied Biosystems 380A DNA synthesizer by the phosphoramidite method as described previously (3). The pair P4 (P4A, 5’-AGG CTC AGG TCA TAC TGG CGT GGA 3’ and P4B, 5’-GGA TCA AAC AGA TCG GTG ACT GGG T3’) was specific to the M. pneumoniae P1 adhesin gene and amplified a 345-bp fragment from nucleotides 3947 to 4291 (GenBank accession no. M18639). The pair G3 (G3A, 5’-GCT TTA AAC CTG GTA ACC AGA 3’ and G3B, 5’-GAG CGT TAG AGA TCC CTG TTC TGT TA 3’) was specific to the M. genitalium adhesin gene and amplified a 507-bp fragment from nucleotides 3754 to 4260 (GenBank accession no. M31431). The primers were chosen to have long but equal normalized length (24) to allow the use of a high annealing temperature, which would reduce the possibility of obtaining unwanted bands originating from nonspecific amplification.

PCR amplification and electrophoresis were performed as described previously (3). PCR were performed in a total volume of 50 μl containing 5 μl of 10× PCR buffer (100 mM Tris-HCl [pH 8.3], 500 mM KCl, 27 mM MgCl₂, 0.1% gelatin), 250 μM (each) deoxynucleoside triphosphate (Pharmacia Baie D’Urfe, Quebec, Canada), 1.0 μM of P4 primers, 2 U of Taq DNA polymerase (Promega, Madison, Wis.), and 20 μl of the sample to be amplified. The reaction volume was overlaid with 50 μl of paraffin oil to prevent evaporation. The samples were subjected to 30 cycles of amplification. The samples were electrophoresed on a 1.5% (wt/vol) agarose gel (Promega), followed by ethidium bromide staining and photography.

To verify that the fragments amplified by the pairs of primers P4 and G3 were the ones expected, oligonucleotides specific to internal regions of those fragments were synthesized and used as probes to hybridize Southern blots. The probes were synthesized as described previously (3) except that the labelling was done by the nonradioactive digoxigenin method. Probe 4A4B was specific to the 345-bp fragment of M. pneumoniae DNA amplified by the P4 primers and had the sequence 5’-GAT GTT GAT GGT ATT GTA C 3’ and 4B was specific to the 507-bp fragment of M. genitalium DNA amplified by the G3 primers and had the sequence 5’-GCT TTA AAC CTG GTA ACC AGA 3’.

<table>
<thead>
<tr>
<th>M. pneumoniae culture result</th>
<th>No. of samples with PCR result indicated</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>15b</td>
</tr>
<tr>
<td>−</td>
<td>0</td>
</tr>
<tr>
<td>+</td>
<td>2</td>
</tr>
<tr>
<td>−</td>
<td>283</td>
</tr>
</tbody>
</table>

* Tested simultaneously for Mycoplasma genitalium.

Three of these samples were also positive for M. hominis, and two were also positive for U. urealyticum.

With the isolation of M. pneumoniae from urogenital specimens in early 1995 (10), reported from our laboratory, we thought it worthwhile to use the newer, faster PCR methodology for a larger study of M. pneumoniae incidence in urogenital specimens. Although PCR has been used successfully to detect M. pneumoniae in respiratory specimens, no PCR study has yet been done to detect M. pneumoniae in urogenital specimens. The PCR protocol described by Cadieux et al. (3) was used to detect M. pneumoniae in urogenital specimens. The guidelines of Chewley (4) were followed to prevent carryover contamination from previously amplified PCR products. Appropriate positive and negative controls were also included.

The results shown in Fig. 1a indicate that an M. pneumoniae-positive control (lane 2) and a culture-positive specimen (lane 3) generated the expected 345-bp amplified DNA, while DNA from a negative specimen (lane 4) and from M. genitalium (lane 5) were not amplified. Figure 1b confirms the specificity of P4 primers for the expected 345-bp product and of G3 primers for the expected 507-bp product.
of amplification through the use of a Southern blot, as previously shown by Cadieux et al. (3).

A total of 300 specimens were analyzed by culture and PCR for the presence of *M. pneumoniae* and *M. genitalium*. We obtained 17 samples positive by PCR for *M. pneumoniae*; of these, 15 were also positive by culture (Table 1). *M. genitalium* was not detected in any of the samples in this survey. Figure 2a shows typical bands obtained for some representative positive specimens after PCR amplification and stained by ethidium bromide, while Fig. 2b shows the Southern probe confirmation results for these positive samples. Other organisms commonly found included *U. urealyticum* (130 single isolates plus 16 cocultures with *M. hominis* and 2 cocultures with *M. pneumoniae*). *M. hominis* also appeared alone in 14 specimens and in coculture with *M. pneumoniae* in 3 specimens. The PCR was completely specific, giving a positive result for *M. pneumoniae* cultures.

The female patients in this study reported symptoms of cervicitis, unusual discharge, chronic abdominal pain, vulvitis, unusual urinary symptoms, infertility, recurrent abortions, stillbirths, abdominal pain in pregnancy, and abnormal bleeding, while the male patients reported prostatic or urethral pain, recurrent urethritis, and in some cases, infertility. The age group in which *M. pneumoniae* was isolated ranged from 19 to 49 years. Most of the positive specimens were cervical swabs while in one case it was an urethral swab. Symptoms for the 49 years. Most of the positive specimens were cervical swabs.

In conclusion, our study clearly demonstrates that the PCR method is specific, sensitive, and rapid; that it clearly distinguishes between *M. pneumoniae* and *M. genitalium*; that it can be used in a routine clinical laboratory; and that it should be considered the method of choice to detect *M. pneumoniae* in urogenital specimens. Our study also confirms our earlier report on the significant frequency of occurrence of *M. pneumoniae* in the urogenital tract. Considering the known pathogenicity of *M. pneumoniae* to human epithelial tissue as well as the clinical symptoms found in the female patients in this study, further work is clearly needed to determine the role of *M. pneumoniae* in urogenital infections.

REFERENCES


